Pharmaxis banks
Tuesday, 16 September, 2008
Pharmaxis [ASX: PXL] ended FY08 in a strong cash position despite large R&D-related losses for the financial year.
At the end of FY08 Pharmaxis had $112 million in the bank, significantly higher than the $76 million cash position the company reported in 2007.
But the company posted a loss of around $20 million for the financial year, largely due to research and development costs.
This R&D spend includes two projects currently progressing their way through clinical trials.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
